GlassScriptPhysician profile
Willa A Hsueh
NPI 1023036076
$40,218.95
in general payments reported to CMS, 2019-2025
20 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.00 · 2020: $6,816 · 2021: $32.27 · 2022: $154 · 2024: $11K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $8,138 · Travel and Lodging: $5,279 · Food and Beverage: $1,388 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,306.25 |
| Consulting Fee | $8,137.50 |
| Travel and Lodging | $5,279.43 |
| Food and Beverage | $1,387.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $31,819.35 | 2024-2025 | Taltz |
| Novo Nordisk INC | $2,655.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $2,623.48 | 2020-2024 | |
| Intercept Pharmaceuticals, INC. | $2,100.00 | 2020 | |
| Glaxosmithkline, LLC. | $150.56 | 2022-2025 | Shingrix, Arexvy |
| Ucb, INC. | $121.19 | 2025 | Bimzelx |
| Abbvie INC. | $120.21 | 2025 | |
| Madrigal Pharmaceuticals | $111.56 | 2025 | Rezdiffra |
| Lilly USA, LLC | $107.44 | 2024-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.61 | 2025 | |
| Sanofi-Aventis U.S. LLC | $58.48 | 2025 | |
| Dexcom, INC. | $58.32 | 2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $49.39 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $46.08 | 2024-2025 | Freestyle Libre 3, Eterna |
| Amarin Pharma, INC. | $35.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $22.24 | 2025 | |
| Ascendis Pharma Endocrinology INC | $20.19 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $15.18 | 2025 | Gvoke Hypopen |
| Amgen INC. | $15.08 | 2025 | Tepezza |
| Corcept Therapeutics | $14.62 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willa Hsueh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.